Pharmacokinetics, tissue distribution and mass balance of radiolabeled dihydroartemisinin in male rats

Malaria Journal

Volumn 8, Issue 1, 2009, Pages

  Xie, Lisa H ^a   Li, Qigui ^a   Zhang, Jing ^a   Weina, Peter J ^a  

^a WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBON 14; COTECXIN; DIHYDROARTEMISININ; DIHYDROARTEMISININ C 14; DIHYDROARTEMISININ PLUS PIPERAQUINE; UNCLASSIFIED DRUG; ANTIMALARIAL AGENT; ARTEMISININ DERIVATIVE; CARBON;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BLOOD BRAIN BARRIER; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BRAIN LEVEL; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG TISSUE LEVEL; ENTEROHEPATIC CIRCULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; NONHUMAN; RADIOACTIVITY; RAT; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; ANIMAL; DRUG EFFECT; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INTRAVENOUS DRUG ADMINISTRATION; METABOLIC CLEARANCE RATE; METABOLISM; METABOLOME; PROTEIN BINDING; SPRAGUE DAWLEY RAT; TANDEM MASS SPECTROMETRY; TISSUE DISTRIBUTION;

ANIMALS; ANTIMALARIALS; AREA UNDER CURVE; ARTEMISININS; BLOOD-BRAIN BARRIER; CARBON RADIOISOTOPES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; MALE; METABOLIC CLEARANCE RATE; METABOLOME; PROTEIN BINDING; RATS; RATS, SPRAGUE-DAWLEY; TANDEM MASS SPECTROMETRY; TISSUE DISTRIBUTION;

EID: 67650699244     PISSN: None     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/1475-2875-8-112     Document Type: Article

References (33)

1. Absence of time-dependent artesunate pharmacokinetics in healthy subjects during 5-day oral administration. LT Diem Thuy L Ngoc Hung PT Danh K Na-Bangchang, Eur J Clin Pharmacol 2008 64 993 998 10.1007/s00228-008-0506-6 18600318
2. Anorectic toxicity of dihydroartemisinin, arteether and artemether in rats following multiple intramuscular doses. Q Li TG Brewer JO Peggins, International J Toxicol 1998 17 663 676 10.1080/109158198225900
3. Neurotoxicity and efficacy of arteether related to its exposure times and exposure levels in rodents. Q Li SR Mog YZ Si DE Kyle M Gettayacamin WK Milhous, Am J Trop Med Hyg 2002 66 516 525 12201585 (Pubitemid 34894900)
4. In vitro neurotoxicity of artemisinin derivatives. WG McLean SA Ward, Med Trop (Mars). 1998 58 3 Suppl 28 31 10212894
5. Neurotoxicity of artemisinin analogs in vitro. DL Wesche MA DeCoster FC Tortella TG Brewer, Antimicrob Agents Chemother 1994 38 1813 1819 7986012 (Pubitemid 24250729)
6. Bioavailabilty and pharmacokinetics of dihydroartemisinin, arteether, artemether, artesunic acid and artelinic acid in rats. Q Li JO Peggins L Fleckenstein K Masonic MH Heiffer TG Brewer, J Pharm Pharmacol. 1998 50 2 173 182 9530985 (Pubitemid 28102574)
7. Pharmacokinetic comparison of artesunate and dihydroartemisinin in beagle dogs. Q Li C Carpenter C Trotman AK Kathcart R Donahue WK Milhous, Am J Trop Med Hyg 1999 61 274
8. A pharmacokinetic and pharmacodynamic study of artesunate for vivax malaria. KT Batty AT Le KF Ilett PT Nguyen SM Powell CH Nguyen XM Truong VC Vuong VT Huynh QB Tran VM Nguyen TM Davis, Am J Trop Med Hyg 1998 59 823 827 9840605 (Pubitemid 28524545)
9. A pharmacokinetic and pharmacodynamic study of intravenous vs oral artesunate in uncomplicated falciparum malaria. KT Batty LTA Thu TME Davis KF Ilett TX Mai NC Hung NP Tien SM Powell HV Thien TQ Binh NV Kim, Br J Clin Pharmacol 1999 45 123 129 10.1046/j.1365-2125.1998.00655.x
10. In vitro stage-specific sensitivity of Plasmodium falciparum to quinine and artemisinin drugs. TS Skinner LS Manning WA Johnston TME Davis, Int J Parasit 1996 26 519 525 10.1016/0020-7519(96)89380-5
11. Artesunate versus quinine for treating severe malaria. KL Jones S Donegan DG Lalloo, Cochrane Database Syst Rev 2007 4 CD005967 17943870
12. Clinical trials of artemisinin and its derivatives in the treatment of malaria in China. GQ Li XB Guo LC Fu HX Jian XH Wang, Trans R Soc Trop Med Hyg 1994 88 Suppl 1 S5 6 10.1016/0035-9203(94)90460-X 8053027
13. An overview of the clinical use of artemisinin and its derivatives in the treatment of falciparum malaria in Viet Nam. TT Hien, Trans R Soc Trop Med Hyg 1994 88 Suppl 1 S7 S8 10.1016/0035-9203(94)90461-8 8053033
14. Guidelines for the Treatment of Malaria. WHO, World Health Organization, Geneva 2006 http://www.who.int/malaria/treatmentguidelines.html
15. Artemether-lumefantrine versus dihydroartemisinin-piperaquine for treating uncomplicated malaria: a randomized trial to guide policy in Uganda. A Yeka G Dorsey MR Kamya A Talisuna M Lugemwa JB Rwakimari SG Staedke PJ Rosenthal F Wabwire-Mangen H Bukirwa, PLoS ONE 2008 3 e2390 18545692 10.1371/journal. pone.0002390
16. Antimalarial drug resistance and combination therapy. NJ White, Philos Trans R Soc Lond B Biol Sci 1999 354 739 749 10365399 10.1098/rstb.1999.0426
17. Efficacy and safety of dihydroartemisinin-piperaquine. HY Myint EA Ashley NP Day F Nosten NJ White, Trans R Soc Trop Med Hyg 2007 101 858 866 10.1016/j.trstmh.2007.05.018 17659311
18. The evaluation of radiolabeled artesunate on tissue distribution in rats and protein binding in humans. Q Li LH Xie A Haeberle J Zhang P Weina, Am J Trop Med Hyg 2006 75 817 826 17123971 (Pubitemid 351627524)
19. Guideline for Industry: Toxicokenetics: The assessment of systemic exposure in toxicity studies. FDA, FDA/ICH S3A 1995 http://www.fda.gov/cder/ guidance/ichs3a.pdf
20. Serum protein binding characteristics of cyproterone acetate, gestodene, levonorgestrel and norethisterone in rat, rabbit, dog, monkey and man. QG Li M Hümpel, J Steroid Biochem 1990 35 319 326 10.1016/0022-4731(90)90291-Y 2137890
21. Comparison of HPLC with electrochemical detection and LC-MS/MS for the separation and validation of artesunate and dihydroartemisinin in animal and human plasma. Y Gu Q Li V Melendez PJ Weina, J Chromatography B 2008 867 213 218 10.1016/j.jchromb.2008.04.019
22. Assessment of the effect of malaria infection on hepatic clearance of dihydroartemisinin using rat liver perfusions and microsomes. KT Batty KF Ilett G Edwards SM Powell JM Maggs BK Park TME Davis, Br J Pharmacol 1998 125 159 167 9776356 10.1038/sj.bjp.0702023
23. The rat biliary metabolites of dihydroartemisinin, an antimalarial endoperoxide. JL Maggs S Madden LP Bishop PM O'Neill BK Park, Drug Metab Dispos 1997 25 1200 1204 9321524 (Pubitemid 27446591)
24. Metabolism and pharmacokinetics of qinghaosu and its derivatives. China Cooperative Research Group on Qinghaosu and its Derivatives as Antimalarials, J Tradit Chin Med 1982 2 25 30 6765844
25. The penetration of anti-infectives into the central nervous system. BP Kearney FT Aweeka, Neurol Clin. 1999 17 4 883 900 10.1016/S0733-8619(05)70171-7 10517933
26. The effect of food and bile acid administration on the relative bioavailability of cyclosporin. A Lindholm S Henricsson R Dahlqvist, Br J Clin Pharmacol 1990 29 541 548 2350530 (Pubitemid 20161303)
27. Metabolic fate of ethyl O-[N-(p-carboxyphenyl)-carbamoyl] mycophenolate (CAM), a new antitumor agent, in experimental animals. Y Matsuzawa T Nakase, J Pharmacobiodyn 1984 7 776 783 6520700 (Pubitemid 15179869)
28. Morphine pharmacokinetics and effects on salivation and continuous reaction times in healthy volunteers. D Westerling L Frigren P Höglund, Ther Drug Monit 1993 15 364 374 10.1097/00007691-199310000-00003 8249042 (Pubitemid 23297238)
29. Bile flow but not enterohepatic recirculation influences the pharmacokinetics of ranitidine in the rat. AB Suttle KL Brouwer, Drug Metab Dispos 1994 22 224 232 8013278 (Pubitemid 24099756)
30. Biliary excretion, metabolism and enterohepatic circulation of buprenorphine. D Brewster MJ Humphrey MA McLeavy, Xenobiotica 1981 11 189 196 10.3109/00498258109045291 7293215
31. Pharmacokinetic analysis of enterohepatic circulation of etodolac and effect of hepatic and renal injury on the pharmacokinetics. T Ogiso T Kitagawa M Iwaki T Tanino, Biol Pharm Bull 1997 20 405 410 9145219 (Pubitemid 27213002)
32. Rapid liver metabolism, urinary and biliary excretion, and enterohepatic circulation of 16 alpha-radioiodo-17 beta-estradiol. A Scharl MW Beckmann JE Artwohl S Kullander JA Holt, Int J Radiat Oncol Biol Phys 1991 21 1235 1240 1938522
33. Hepatic metabolism, biliary clearance and enterohepatic circulation of thyroid hormone. TJ Visser M Rutgers WW de Herder SJ Rooda MP Hazenberg, Acta Med Austriaca 1988 15 Suppl 1 37 39 3051833